Sensei biotherapeutics announces new clinical data from the ongoing phase 1/2 combination trial of sns-301 in patients with squamous cell carcinoma of the head and neck

– data continue to show that sns-301 in combination with pembrolizumab is well tolerated –

SNSE Ratings Summary

SNSE Quant Ranking